0000950170-24-081878.txt : 20240705 0000950170-24-081878.hdr.sgml : 20240705 20240705163002 ACCESSION NUMBER: 0000950170-24-081878 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240703 FILED AS OF DATE: 20240705 DATE AS OF CHANGE: 20240705 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Pizzuti Dana CENTRAL INDEX KEY: 0001948238 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38583 FILM NUMBER: 241102864 MAIL ADDRESS: STREET 1: C/O CRINETICS PHARMACEUTICALS, INC. STREET 2: 10222 BARNES CANYON ROAD, BUILDING 2 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Crinetics Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001658247 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 263744114 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10222 BARNES CANYON ROAD, BLDG. #2 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-450-6464 MAIL ADDRESS: STREET 1: 10222 BARNES CANYON ROAD, BLDG. #2 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 ownership.xml 4 X0508 4 2024-07-03 false 0001658247 Crinetics Pharmaceuticals, Inc. CRNX 0001948238 Pizzuti Dana C/O CRINETICS PHARMACEUTICALS, INC. 6055 LUSK BOULEVARD SAN DIEGO CA 92121 false true false false Chief Med and Dev Officer true Common Stock 2024-07-03 4 M false 14375 16.89 A 42882 D Common Stock 2024-07-03 4 S false 14375 44.87 D 28507 D Stock option (Right to Buy) 16.89 2024-07-03 4 M false 14375 0 D 2032-10-10 Common Stock 14375 153417 D The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $44.87 per share. The range of sales prices on the transaction date was $44.24 to $45.55 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request. Includes 721 shares acquired under the Issuer's Employee Stock Purchase Plan. The option is exercisable as follows: 25% of the shares subject to the option vest on September 30, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Marc Wilson, as attorney-in-fact 2024-07-05